BIONDVAX PHARMACEUTICALS-ADR (BVXV)

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI”

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” ...

BiondVax Reports Second Quarter Financial Results and Provides Business Update

BiondVax Reports Second Quarter Financial Results and Provides Business Update

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing,...

Nasdaq grants BiondVax extension to regain compliance with listing rules (NASDAQ:BVXV)

BiondVax Pharmaceuticals (BVXV) said Nasdaq provided an extension until October end as it reviewed the biotechnology company's multi-faceted plan to regain compliance with Nasdaq’s...

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing,...

BiondVax stock +6% on license agreement to develop antibodies (NASDAQ:BVXV)

U.S.-listed shares of BiondVax Pharmaceuticals (BVXV) jumped as much as 32% on Monday on a license agreement to develop antibodies. Read more here.

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on...

BiondVax to Present at BIO-Europe Spring

BiondVax to Present at BIO-Europe Spring

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on...

IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BiondVax Presenting at BIO CEO & Investor Conference

BiondVax Presenting at BIO CEO & Investor Conference

JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on...

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2  Data further...

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral...

BiondVax to Present at Biotech Showcase 2023

BiondVax CEO Issues Letter to Shareholders

BiondVax CEO Issues Letter to Shareholders

JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on...

BiondVax Announces Closing of $8 Million Underwritten Public Offering

BiondVax Announces Closing of $8 Million Underwritten Public Offering

JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(“Company”), a biotechnology company, which...